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A growing need for nonlethal methodology for popula- 
tion control of nuisance or damaging species of 
wildlife has fostered research in immunocontraceptive 
vaccine technology. Kirkpatrick et al. (1990) demon- 
strated that reproductive rates of feral horses can be 
reduced by vaccinating these animals with native 
porcine zona pellucida (PZP). Turner et al. (1992) 
demonstrated that PZP was effective as an 
immunocontraceptive in the white-tailed deer 
(Odocoileus virginianus). Recent advancements in 
immunology and molecular biology have made it 
possible to produce and administer genetically engi- 
neered contraceptive vaccines, thus making reproduc- 
tive control a very promising alternative in wildlife 
management. 
In a previous study by Turner and Kirkpatrick 
(1991), the vaccine was delivered by darting or 
biobullet. This remote delivery is valuable for special 
applications. However, in order for this technology to 
have wide application, one must have a mode of 
application that can disseminate the vaccine to a large 
segment of a wildlife population at a reasonable cost 
(Garrott et al. 1992). 
The most logical means of vaccine application to 
free-roaming animals is by oral delivery. Oral vaccina- 
tion, however, is not without its problems (Bloom 
1989). Because vaccines are proteins, they need a 
protective mechanism to prevent digestion in the 
gastrointestinal tract. Baiting with vaccines should be 
as species specific as possible and yet be designed to 
reach a large proportion of the selected wildlife 
population. Oral delivery of immunocontraceptive 
vaccines is an untested area of technology that will 
need several years of developmental research before 
the first vaccines are available for entry into the 
registration process. 
The purpose of this paper is to review the 
immunological concepts of vaccination and how they 
may apply to immunocontraception, review the current 
technology of oral immunization, and propose some 
applications for oral immunocontraception in free- 
roaming pest vertebrates. 
Reproduction and Immunology 
Mammalian and avian reproduction involves interac- 
tion of spermatozoa and oocytes contributed by the 
male and female, respectively. Both these gametes 
have unique surface glycoprotein receptors against 
which an immune response can be elicited. The 
development of these gametes and corresponding 
hormones is under the control of follicle-stimulating 
hormone (FSH) and luteinizing hormone (LH), gona- 
dotropins secreted from the pituitary and flowing 
through the bloodstream to the gonads. Secretion of 
the gonadotropins is in turn regulated by gonadotro- 
pin-releasing hormone (GnRH), which also has a role 
in sexual receptivity that is in addition to its regulation 
of FSH and LH release and the stimulation of ovula- 
tion. lmmunocontraception involves producing anti- 
bodies against these reproductive hormones and 
gamete proteins that will interfere with their biological 
activity. 
The power and efficiency of vaccines in combating 
infectious diseases is well recognized and accepted. 
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The vast majority of vaccine research is concerned 
with the development of new and improved vaccines 
against viral and bacterial diseases. Antidisease 
vaccines are based on using immunologically foreign 
antigens, such as surface glycoproteins of viruses and 
bacteria, to stimulate the immune system to form 
antibodies that attack live viruses and bacteria just as 
they would the glycoproteins. 
In order to understand the concepts of 
immunocontraception, one must understand how the 
immune system defends itself against outside organ- 
isms (Silverstein 1989). Development of infections 
and resulting immune responses are constantly in 
process because people live in a world filled with 
micro-organisms. Every facet of our existence brings 
us into contact with bacteria, fungi, viruses and a 
diversity of parasitic or potentially parasitic life forms. 
Yet we possess a rich, harmless, natural microflora on 
all body surfaces, within all body orifices, and through- 
out most of the gastrointestinal tract. Even vital 
digestive functions are mediated partly by the gas- 
trointestinal flora. The body is able to differentiate 
normal flora and self-proteins from pathogens through 
a process called immune tolerance. 
Antifertility vaccines are directed against self- 
reproductive antigens, either hormones or proteins, to 
which the recipient is normally immunologically 
tolerant (Jones 1983). These antigens are made 
"foreign" by coupling them to a protein foreign to the 
animal. The resultant vaccine induces immunity which 
interferes with the biological activity of that particular 
antigen. The result can be infertility (fig. 1). 
An immunological approach to contraception is 
attractive because it requires only periodic vaccina- 
tion. The approach is physiologically sound in the 
sense that antibodies induced in the target animal 
interfere with reproduction without the constant 
medication. 
lmmunocontraception occurs when fertility is 
reduced by means of antibodies attaching to and 
interfering with the biological activity of hormones or 
reproductive tract proteins. lmmunization against 
most reproductive antigens generally gives rise to a 
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reversible response. Antibodies decline in the course 
of time, and animals regain fertility (Dunbar and 
Schwoebel 1988). 
Systemic Vaccination 
Dose amount, frequency and timing, immunogenicity 
of the antigen vaccine preparation, and mode of 
immunization all influence the immune response. The 
nature of the immune response required for an anti- 
fertility vaccine is equivalent to the response obtained 
by immunization. Rendering reproductive self-antigens 
immunogenic involves conjugating these self-molecules 
with foreign substances in order to break the state of 
tolerance associated with these molecules. These 
vaccines must be designed to react with macrophages 
(the antigen presenting cells) as well as with the two 
immune-processing cells (T and 6). For example, the 
T cells receive the antigen from the macrophage and 
present the foreign material to the B cells. Enhance- 
ment of B-cell activity is essential to the production of 
high levels of antibodies as well as creation of B 
memory cells to that specific antigen. 
Traditional immunization has always been 
associated with adjuvants (nonspecific immune 
stimulants). The most common adjuvant is Freund's 
complete adjuvant (FCA). This substance is a mixture 
of mineral oil and killed bacteria cells. Booster injec- 
tion is performed with Freund's incomplete adjuvant 
(FIA) (minus the killed bacteria) to prevent abscesses 
at the injection site. The protein to be injected is 
dissolved in water and mixed with the oily adjuvant to 
form a water-in-oil emulsion. This emulsion provides a 
depot at the injection site allowing a slow release of 
the immunogen to the immune system. The optimal 
length of antigen presence for maximum antibody 
production is unknown; however, if antigen presence 
is too short, the antibody quantity is suboptimal. 
Chronic presence of antigen leads to antigen toler- 
ance and a lack of antibody production response. 
The immune system, both systemic and mucosal, 
seems to respond best by giving a priming dose 
followed in several weeks by a booster dose. A single 
dose produces a short-lived antibody response and 
does not result in a long-lasting memory response. 
Many times, the best response is observed when the 
animal is boosted several months after the original 
antigen exposure. Continued presence of the antigen 
for several weeks is important for a long-lasting 
immune response. Slow-release vehicles such as 
microspheres or liposomes can provide this effect. 
The standard form of vaccination involves 
50-100 pg of antigen for small animals (mice to 
rabbits) and 200-400 pg for larger animals. The 
antigen is mixed with FCA to produce a thick water-in- 
oil emulsion. This emulsion is injected into the animal 
using multiple subcutaneous, intradermal, or intramus- 
cular sites. Booster doses use the same or slightly 
less antigen in FIA. When incomplete Freund's is 
used for boosters, abscesses at the site of injection 
generally do not form. Highly immunogenic antigens 
can produce sufficient antibody with doses of 5 to 10 pg. 
Scientists at the Denver Wildlife Research 
Center (DWRC) have demonstrated that the hypotha- 
lamic hormone GnRH, made foreign by coupling to 
keyhole limpet hemocyanin (KLH), can sterilize both 
sexes of wild Norway rats (Rattus norvegicus) for up 
to a year. White-tailed deer immunized with a porcine 
glycoprotein (PZP), the zona pellucida that surrounds 
all mammalian oocytes, remained sterile for at least 
two breeding seasons. 
Oral Vaccination 
Mucosal Immune System 
The pharyngeal and intestinal mucosae represent a 
major interface with the external environment and 
come in contact with food and products of food 
digestion, ingested micro-organisms, drugs, and the 
vast quantity of resident flora that populate the distal 
small intestine and colon (Mestecky 1987). 
The intestine is the body's largest immunologic 
organ. It comprises 70-80 percent of all of the body's 
immunoglobulin (lg) (antibody)-producing cells and 
produces more secretory lg (SIgA) than the total 
production of serum lg in the body. The primacy of the 
intestine in making lg is not surprising because the 
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majority of infectious disease organisms are first 
encountered through the intestinal mucosal mem- 
branes. The main antibody produced by the mucosal 
immune system is SIgA. Intestinal SlgA response is of 
relatively short duration, lasting from 2 to 4 weeks. 
The SlgA system exhibits potent immunologic memory 
and can be repeatedly stimulated by renewed contact 
with antigen. Systemic IgG production may also be 
stimulated by oral vaccination, and the presence of 
IgG as a result of vaccination may be detected in 
serum years later. It is the serum IgG that provides 
the long-term interference with the biological activity of 
reproductive hormones and proteins. 
Immune follicles, including tonsils, are located in 
the pharyngeal area at the entrance to both the 
respiratory and digestive tracts. The pharyngeal area 
of the throat may be considered the first line of mucosal 
defense and immune response. As a second line of 
defense, thousands of lymphoid follicles are located in 
the distal portion of the small intestine. Aggregates of 
these follicles called Peyer's patches (PP) are also 
found throughout the small intestine. The lumenal 
surface of PP are covered by an epithelium which 
contains a unique cell type termed the M cell (Childers 
et al. 1990). Intact viruses and micro-organisms and 
particulate antigens up to 10 bm in size are taken up 
by M cells for antigen delivery to the underlying 
lymphoid cells. This uptake of micro-organisms 
enhances the ability of the host to respond immuno- 
logically to a microbial challenge and fight off an 
infection. These antigens activate T and B cells and, 
along with macrophages, soon migrate out of the PP 
to the mesenteric lymph nodes and into the blood- 
stream via the thoracic duct, thereby presenting the 
antigen to the systemic immune system (fig. 2). 
Oral Delivery of Antigen to the Intestine 
Many factors can influence the expression of mucosal 
immunity to a specific antigen. Most proteins are 
rather poor immunogens when given orally. This is 
the reason so few vaccines are currently administered 
by this route. 
Effective mucosal immunogens appear to have 
certain characteristics: (1) They are not degraded in 
the mucosal environment (e.g., the intestine); (2) they 
Intestinal Immune System 






Figure 2. The small intestine contains thousands of immune 
follicles. Aggregates of these follicles are called Peyer's patches 
(PP). Their surface contains a unique cell type. the M cell, which 
takes up intact viruses, bacteria, and particulate antigens up to 
10 pm in size. Once inside the PP the antigens are processed by 
the macrophage and presented to the immune system. 
can bind to and penetrate into the mucosal epithelium 
(thus allowing efficient uptake in the PP, as typified by 
cholera toxin (CT), one of the most effective mucosal 
immunogens known; and (3) they may also have 
adjuvant immunostimulating activity (Holmgren et al. 
1992, McGhee and Kiyono 1994). 
Live micro-organisms with mucosal adhesive 
properties are highly effective mucosal immunogens; 
killed and inert antigens without mucosal binding 
properties are poor mucosal immunogens. Most food 
antigens are poor mucosal immunogens because they 
are rapidly degraded into nonimmunogenic fragments 
in the mucosal environment. Food antigens generally 
do not bind to epithelial receptors. 
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As pointed out previously, immune lymphoid 
follicles are located in the pharyngeal area as well as 
distal portion of the small intestine. Most oral immuni- 
zation studies use the gavage technique, which 
means the antigen was delivered into the stomach 
through a blunted needle. Lavage delivery, in which 
the antigen is delivered in the pharyngeal area, can 
stimulate the immune follicles in this area as well as in 
the small intestine. Delivery of unencapsulated protein 
antigens to the pharyngeal area may be an effective 
means of oral immunization since it precedes the 
stomach's digestive enzymes. 
Enteric-coated capsules are commonly used for 
delivery of drugs to the small intestine. Enteric 
capsules are resistant to acid but are soluble in the 
alkaline solution of the small intestine. They provide 
only one-half of the formula of effective antigen 
delivery (i.e., protection from the stomach) because 
they generally cannot be made small enough to be 
taken up by the PP. Also, enteric-coated vaccines can 
get the protein past the stomach, dissolve, and 
release the antigen in the small intestine, but pro- 
teolytic enzymes in the small intestine may digest 
these proteins into nonimmunogenic peptides before 
they are absorbed by the immune cells. The safest 
way to deliver the antigen orally is to protect it until it is 
taken up by the PP and delivered to macrophages. 
Combining two approaches-(I) enteric coating 
or using delivery vehicles that slow the intestinal 
degradation of the antigen and (2) targeting the 
vaccine design to attach to the immune follicles with M 
cell binding-could lead to an effective antigen uptake 
and potentiation of mucosal immune response. 
The quantity of antigen used in oral immunization 
depends on how well the antigen is protected from 
degradation and how immunogenic it is. The antigen 
dose may vary from 12.5 pg to 1 g per dose, with 
larger animals receiving the larger quantities of 
antigen. Most studies indicate that two doses given 
3-4 weeks apart are needed to produce a long-lasting 
immune response. Ahren et al. (1993) found that a 
third dose given within 3 weeks was counterproduc- 
tive, probably because SlgA stimulated from the 
second dose interfered with the uptake of the antigen. 
Two oral doses of a live salmonella vector 
produced IgG responses similar to the response of a 
systemic vaccination of the killed form of the same 
vaccine (Morona et al. 1994). Oral boosting after 
42 days was needed for this response. A single dose 
or boosting after 14 days gave a much lower antibody 
titer. 
Scientists at DWRC have demonstrated that 
white-tailed deer can be successfully vaccinated using 
a genetically engineered Bacillus Calmette Guerin 
(BCG). These bacteria were designed to deliver an 
outer surface protein A (Osp A) antigen onto the 
surface of the bacteria. A good IgG response to the 
Osp A antigen was demonstrated after two oral doses 
of bacteria. DWRC is also testing different oral 
immunocontraceptive vaccines in wild Norway rats. 
Immune Tolerance 
The constant systemic presence of antigen can induce 
a state of immune tolerance in which antibody produc- 
tion is reduced (Ernst et al: 1988). This process is 
probably a protective mechanism to prevent the 
animal from an excessive immune response. What is 
excessive depends on the antigen. However, gram 
quantities of antigen are generally considered exces- 
sive. The mucosal immune system seems to have a 
built-in limitation in terms of the magnitude of response 
to any single immunogen (oral immune tolerance). 
This limitation is in contrast to the systemic immune 
system, which responds vigorously to nonself-anti- 
gens. It would be impossible and perhaps even 
harmful for the intestine to mount a vigorous immune 
response to each of the thousand foreign antigens it 
encounters each day. The term "oral tolerance" is 
used when the animal's immune system ceases to 
respond to a given antigen. Oral tolerance is com- 
monly found when a large dose of an antigen is given 
or when the antigen is highly immunogenic and 
therefore likely to cause the animal harm due to a 
severe immunologic reaction. An example of this 
second type of antigen is a bacterial surface lipopro- 
tein, lipopolysaccharide (LPS). 
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Stok et al. (1994) discovered that conjugating 
cholera toxin (CT) to ovalbumin and revaccinating with 
the conjugate orally could reverse an earlier ovalbu- 
min-induced oral immune tolerance. 
Oral Vaccine Delivery Vehicles 
Synthesized Vectors 
Microspheres-Biodegradable microspheres have 
been used as a slow-release antigen-delivery system. 
These spheres are copolymers of DL-lactide and 
glycolide that are synthesized to contain trapped 
antigen. When these spheres are injected into the 
host animal, they dissolve, slowly releasing the 
antigen. The microsphere can be designed to deliver 
the antigen for from 1 week to several months, depend- 
ing on the size and the polymer ratio of lactide to 
glycolide. In most applications, microspheres have 
been given systemically; however, they can be given 
orally (Eldridge et al. 1989 and 1990). Microspheres 
of 1-10 pm are taken up by the PP; however, the 
efficiency of the uptake is only 1-2 percent. The 
remaining microspheres pass out of the intestine. The 
microspheres taken up by the PP dissolve, releasing 
the antigen directly to the immune system. 
Liposomes-Liposomes are spherical, artificial 
biological membranes made up of phospholipids and 
cholesterol (Alving et al. 1991). Liposomes contain 
lipids, chosen for their stability in the gastrointestinal 
tract. These lipids can protect the antigen from 
gastrointestinal degradation. Cholesterol in the 
liposome stabilizes the membrane and makes it 
attractive to the macrophage because of its lipophilic 
nature. The phospholipids in liposomes are 
amphipathic, i.e., they possess a hydrophilic (polar) 
head and hydrophobic (hydrocarbon) tail. In an 
aqueous medium, phospholipids exist as micelles or 
bilayers; the polar heads are at the outer layer due to 
their affinity to water (fig. 3). 
Because of the nature of the membrane, the 
liposome mimics the microbial cell when the liposome 
is presented to the immune system. During the 
synthesis of the liposome, antigen is trapped inside, 
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Figure 3. Liposomes are spherical artificial biological membranes. 
During the synthesis of the liposome. antigen is trapped inside the 
sphere. The resuit is a protective vehicle for oral delivery of the 
antigen. Cholera toxin B 1s attached to the outer surface of the 
liposome to provide intestinal adhesive propertes Ths adhesion 
to the intestine enhances immune response to the liposome and ts  
antigen contents. 
providing a protective vehicle for delivery of the 
protein antigen. The liposome acts as an antigen 
microcarrier and an adjuvant, capable of targeting the 
antigen directly to the PP. Liposomes have been used 
to deliver the antigen systemically or orally. When 
given orally, liposomes with a diameter less than 10 pm 
are preferentially taken up by the PP and may persist 
there for up to several weeks (Alving et al. 1991). 
Liposomes, especially small ones (1-2 pm), can be 
expected to reach the blood circulation rapidly through 
the intestinal lymphatics. 
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Liposomes Enhanced With Cholera Toxin B-Until 
recently, based on the relatively poor mucosal immu- 
nogenicity of soluble antigens, it was widely assumed 
that only live vaccines would effectively stimulate a 
mucosal immune response (Nedrud and Lamm 1991). 
Recent understanding of the mechanisms by which 
pathogenic viruses and bacteria colonize and infect 
the intestinal tract gives researchers new tools to 
develop successful oral vaccines. For example, a 
bacterium must survive the presence of the stomach's 
acid and proteolytic enzymes in order to infect the 
small intestine successfully. After surviving the 
stomach, the bacterium must have surface adhesive 
properties allowing it to adhere to and colonize the 
intestinal wall, resulting in an infection. Bacteria 
without these adhesive properties will be carried out of 
the gut with undigested food material. 
Because of their lipophilic nature, liposomes are 
avidly taken up by the macrophages (Rooijen 1990). 
However, the liposome must bind to the mucosal 
surface of the intestine before it can be taken up. This 
rnucosal adhesive property increases the mucosal 
uptake resulting in greater efficiency and allowing one 
to use a smaller oral vaccine dose. The most com- 
mon liposome adhesive is the bacterial lectin CT, a 
member of a family of enterotoxins produced by 
several strains of enteropathogenic bacteria (Ahren et 
al. 1993, McGhee 1992, Mestecky and McGhee 
1989). Lectins have multiple binding sites and can 
bind to receptors on the liposome as well as to intesti- 
nal receptors. 
CT consists of two subunits-alpha (CTA), which 
has the toxic properties, and beta (CTB), which has 
the adhesive or mucosal binding properties. CTB 
bound to the liposome provides the adhesive proper- 
ties without the toxicity associated with CT. The CTB 
bound to the ganglioside GM, receptor inserted in the 
liposome also binds to the ganglioside GM, receptors 
present on the surface of intestinal epithelial cells, 
thus providing the binding activity needed for mucosal 
antigens (fig. 3). 
Heat-labile toxin (LTB) from pathogenic Escherichia 
coli bacteria represents another adhesive lectin that 
can be attached to liposomes to provide an intestinal 
mucosal binding. 
Live Vectors 
The common forms of existing vaccines are killed 
bacteria or modified live viruses that, when injected 
into the host animal, produce immunity by producing 
antibodies against surface proteins of these organ- 
isms. New techniques in molecular biology have 
introduced the concept of delivering the vaccine 
surface proteins in harmless live bacteria or viruses 
that act as a delivery system and therefore are called 
vectors. Vectors can be used to deliver the vaccine 
proteins systemically or orally. Vectors that are 
effective orally must have the ability to attach or 
adhere to mucosal surfaces. After attachment, these 
vectors are taken in by the mucosal immune system 
and thereby deliver the vaccine proteins directly to the 
immune system. Nonattaching vectors would be 
carried out of the intestine with the food bulk. 
The ideal immunocontraceptive vaccine should 
be species specific; however, at the present time, 
species specificity is difficult to achieve. Live vectors 
can help provide species specificity by employing 
species-specific viruses or bacteria, such as 
swinepox, which was used to develop a vaccine 
carrier for the control of the feral hog. 
Viral Vectors-The DNA representing several vac- 
cines has been inserted into harmless viruses. The 
inserted DNA synthesizes the vaccine protein as the 
virus multiplies in the host animal, thereby vaccinating 
the animal. The most noted viral vector has been the 
vaccinia virus a member of the poxvirus family (Moss 
1991). This virus has been genetically engineered to 
deliver a rabies vaccine. Given orally, the harmless 
vaccinia virus multiplies in the body and synthesizes a 
surface rabies protein. Antibodies produced against 
this protein protect the animal against a future rabies 
virus infection. This viral construct has been used 
successfully in eliminating most of the rabies in foxes 
and raccoons in Europe (US. Department of Agricul- 
ture, Animal and Plant Health Inspection Service 
1991). The viral vectors can also be designed to 
contain immunocontraceptive proteins (Morell 1993). 
Bacterial Vectors-As in viral vectors, bacteria can 
be genetically rendered harmless (nonpathogenic) and 
have immunocontraceptive vaccine DNA inserted into 
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them. This recombinant bacteria can deliver a 
irnmunocontraceptive protein, coded by the inserted 
DNA, to an animal host. The two bacterial vectors in 
use today are an attenuated BCG and a double gene- 
deleted Salmonella typhi bacillus. Both bacteria 
vectors are considered safe and have been used in 
many vaccine delivery applications. S. typhistrains, 
with deletion of two genes, are avirulent in animals, 
birds, and humans. These strains retain the intestinal 
adherence property found in unmodified Salmonella 
spp, and are absorbed by the intestinal immune cells. 
It appears to be safe and effective as a live vector for 
oral delivery of immunocontraceptive vaccines. 
Morona et al. (1994) found that two oral doses of 
a live Salmonella construct elicited serum IgG responses 
that were comparable to intramuscular vaccination 
with formalin-killed Salmonella. Therefore, it appears 
that-even with live vectors-one needs at least two 
presentations of the antigen. 
Live bacterial and viral vectors would be more 
economical to produce than the synthetic vectors; 
however, the public acceptance and safety issues 
have to be addressed. 
Field Applications of Oral 
lmmunocontraceptive Vaccines 
Oral immunocontraceptive protein vaccines are 
untested. The protein vaccine must be mixed into 
liquid or solid baits that require some protection from 
the environment for at least several weeks. The bait 
must be attractive to a large segment of the target 
animal population. Present vaccine designs would 
require baiting an animal population twice about one 
month apart. Vaccine application should start about 
2 months before the start of the breeding season. If 
the vaccine itself is not species specific, the delivery 
system should be. Problems d multiple visits to the 
bait and repeat baiting of dominant animals need to be 
understood in the practical application of population 
control. With the exception of the vaccinia virus rabies 
vaccine, safe use of recombinant bacterial and viral 
vectors has yet to be proven in a field application. 
Summary 
lmmunocontraceptive vaccines delivered by injection 
or by darting have been shown to be a viable tech- 
nique in preventing conception when used in confined 
or limited field applications. However, in order for 
immunocontraception to have widespread success 
against free-roaming animal populations, the vaccine 
must be delivered in an oral form in a designed bait. 
Because oral vaccines are proteins, they are subject 
to digestion by stomach gastric contents; therefore, 
the oral vaccine must be protected by some form of 
encapsulation. Inconsistent antibody responses to 
multiple oral doses may be due to the presence of 
intestinal IgA antibodies, which may prevent uptake of 
the antigen by the intestinal immune system. 
Recent understanding of the mechanisms by 
which pathogenic viruses and bacteria colonize and 
infect the intestinal tract give us new tools to develop 
successful oral vaccines. Synthesized vectors, such 
as biodegradable microspheres and liposomes, can 
protect the protein vaccines and deliver them to the 
mucosal immune cells. Liposomes can be designed 
to contain lectin receptors that mimic the adhesive 
properties of intestinal pathogens, thereby enhancing 
their mucosal uptake and immunogenic properties. 
Understanding the molecular genetics of oral 
pathogenic bacteria and viruses allows one to attenu- 
ate these virulent strains and insert the DNA of the 
vaccine to be expressed. Because these vaccine 
proteins are "self," they need to be linked to the DNA 
of a more immunogenic protein and be expressed 
together by the live vector. The use of these attenu- 
ated live vectors to deliver immunocontraceptive 
vaccines can provide economical vaccines of a 
consistent nature. These new tools should provide the 
basis for successful oral immunocontraceptive vac- 
cines of the future. Successful field application of 
these vaccines needs careful study and is yet to be 
attempted. 
Delivery of lmmunocontraceptive Vaccines 
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